Similar articles

• Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.

  Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D, Possinger K. Schmid P, et al. J Clin Oncol. 2007 Jun 20;25(18):2509-15. doi: 10.1200/JCO.2006.08.8534. J Clin Oncol. 2007. PMID: 17577027 Clinical Trial.
• Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.

  Panasci LC. Panasci LC. J Clin Oncol. 2006 May 20;24(15):2392; author reply 2392. doi: 10.1200/JCO.2006.05.7562. J Clin Oncol. 2006. PMID: 16710042 No abstract available.
• Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials.

  Albain KS. Albain KS. J Natl Cancer Inst. 2004 Dec 15;96(24):1801-4. doi: 10.1093/jnci/djh347. J Natl Cancer Inst. 2004. PMID: 15601631 No abstract available.
• Evolving concepts in the systemic adjuvant treatment of breast cancer.

  Bonadonna G. Bonadonna G. Cancer Res. 1992 Apr 15;52(8):2127-37. Cancer Res. 1992. PMID: 1559216 Review. No abstract available.
• [No advantage to using the CMF-regimen for node positive, postmenopausal, receptor-positive mammary carcinoma with adjuvant tamoxifen therapy].

  Heidemann E. Heidemann E. Strahlenther Onkol. 1998 May;174(5):290-1. doi: 10.1007/BF03038727. Strahlenther Onkol. 1998. PMID: 9614963 Review. German. No abstract available.